Therefore, it is also possible that these more novel MET monoclonal antibodies (mAbs) (eg. ABBV- 400, Telisotuzumab vedotin [57], TR1801-ADC [60]) might show improved tolerability when combined with MEK1/2 inhibitors, more optimal pathway modulation and improved clinical activity in MET-dependent RASMT CRC patients. This evidence concerns the gene MET and colorectal carcinoma.